Please use this identifier to cite or link to this item:
Title: Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
Author: Avila, M.P.
Farah, M.E.
Santos, A.
Duprat, J.P.
Woodward, B.W.
Nau, J.
Issue Date: 2009
Abstract: Background/aims: This study evaluated the short-term safety and feasibility of epiretinal strontium-90 brachytherapy delivered concomitantly with intravitreal bevacizumab for the treatment of subfoveal CNV due to AMD for 12 months. A 3-year follow-up is planned. Methods: In this prospective, non-randomised, multicentre study, 34 treatment-na�ve patients with predominantly classic, minimally classic and occult subfoveal CNV lesions received a single treatment with 24 Gy beta radiation (strontium-90) and two injections of the anti-VEGF antibody bevacizumab. Adverse events were observed. BCVA was measured using standard ETDRS vision charts. Results: Twelve months after treatment, no radiation-associated adverse events were observed. In the intent-to-treat (ITT) population, 91% of patients lost <3 lines (15 ETDRS letters) of vision at 12 months, 68% improved or maintained their BCVA at 12 months, and 38% gained ?3 lines. The mean change in BCVA observed at month 12 was a gain of 8.9 letters. Conclusion: The safety and efficacy of intraocular, epiretinal brachytherapy delivered concomitantly with anti-VEGF therapy for the treatment of subfoveal CNV secondary to AMD were promising in this small study population. Long-term safety will be assessed for 3 years. This regimen is being evaluated in a large, multicentre, phase III study.
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.

Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.